Evidence map›Paper›PMID 40872487›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis.

Tingyang Wei, Zonglin Li, Chu Lin, Yuteng Yang, Changjie Tie, Xiaoling Cai, Fang Lv, Wenjia Yang, Linong Ji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tingyang WeiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Zonglin LiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Chu LinDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Yuteng YangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Changjie TieDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Xiaoling CaiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.ORCID 0000-0002-7881-0543
Fang LvDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Wenjia YangDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Linong JiDepartment of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.

Funding

National Natural Science Foundation of China No.81970698National Natural Science Foundation of China No.81970708Natural Science Foundation of Beijing Municipality No.7202216
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast neoplasmmeta-analysisneoplasmPCSK9iproprotein convertase subtilisin/kexin type 9 inhibitors

Identifiers

PMID40872487
PMCPMC12389645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.